Isomorphic Labs Raises $5 Billion to Turn AI Into Medicine
Isomorphic Labs Raises $5 Billion to Turn AI Into Medicine
Demis Hassabis has spent most of his career trying to teach machines to understand biology. As Isomorphic Labs, the drug discovery startup he founded, has raised a $5 billion Series C, the company said Tuesday, according to reporting from CNBC. The round arrives just over three months after Hassabis stepped back as CEO of Google DeepMind, the AI lab he co-founded before Google acquired it in 2014.
"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI."
The Money Behind the Molecules
The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz participating and Alphabet, Google's parent company, also investing, as CNBC noted. The company plans to use the fresh capital to design and develop new medicines using AI. Isomorphic has been led by Hassabis since it spun out of DeepMind in 2021. Its previous round was a $2.1 billion Series B in May, which means the company has more than doubled its war chest in roughly six months.
A Record Year for AI Drug Discovery
Isomorphic is not operating in a vacuum. As CNBC reported, citing deal-counting platform Dealroom, drug discovery startups have raised $23.2 billion in 2026, a record. Investors are pouring money into tools that promise to use machine learning to find and refine drug candidates faster than traditional methods allow. The major AI labs have joined the race too. Anthropic announced an AI drug discovery program in June, and OpenAI partnered with Novo Nordisk in April, according to the same report.
"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
What Comes Next
Isomorphic says it is building a proprietary drug design engine and a pipeline of therapeutic candidates designed with AI. Hassabis framed the goals in concrete terms: foundational biology models, a deeper understanding of disease systems, and the first therapeutic programs moving toward clinical trials. Those trials are where AI-designed drugs will face their hardest test. Software can predict how a molecule might behave, but only human trials can show whether it actually helps patients. The next few years will reveal whether Isomorphic's models can move beyond impressive funding numbers and into the clinic.
Aaron Rose is the founder and publisher of Tech Reader Magazine, covering system architecture, cloud platforms, and AI policy.